Agenus Inc. is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer and infectious diseases. Headquartered in Massachusetts, the company focuses on activating the body's immune system through a portfolio of checkpoint inhibitors, immune modulators, and cell therapies. Agenus is notable for its proprietary Retrocyte Display antibody expression platform and its development of the QS-21 Stimulon vaccine adjuvant. The company's clinical pipeline is anchored by botensilimab and balstilimab, which are being evaluated as combination therapies for solid tumors such as metastatic colorectal cancer and melanoma. Agenus operates globally, advancing its programs both internally and through strategic partnerships with major pharmaceutical companies like Incyte, Merck, and Gilead Sciences. Additionally, the company advances adoptive cell therapies through its publicly traded subsidiary, MiNK Therapeutics.
